276 related articles for article (PubMed ID: 20136921)
1. Cost-effectiveness analysis of TNF-alpha blockers for the treatment of chronic plaque psoriasis in the perspective of the Italian health-care system.
de Portu S; Del Giglio M; Altomare G; Arcangeli F; Berardesca E; Calzavara-Pinton P; Lotti T; Martini P; Peserico A; Simonacci M; Vena GA; Girolomoni G
Dermatol Ther; 2010; 23 Suppl 1():S7-13. PubMed ID: 20136921
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period.
Nelson AA; Pearce DJ; Fleischer AB; Balkrishnan R; Feldman SR
J Am Acad Dermatol; 2008 Jan; 58(1):125-35. PubMed ID: 17996329
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of biologic therapies for plaque psoriasis.
Ahn CS; Gustafson CJ; Sandoval LF; Davis SA; Feldman SR
Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
[TBL] [Abstract][Full Text] [Related]
4. Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis.
Ferrándiz C; García A; Blasco AJ; Lázaro P
J Eur Acad Dermatol Venereol; 2012 Jun; 26(6):768-77. PubMed ID: 22126264
[TBL] [Abstract][Full Text] [Related]
5. Infliximab for the treatment of adults with psoriasis.
Loveman E; Turner D; Hartwell D; Cooper K; Clegg A
Health Technol Assess; 2009 Jun; 13 Suppl 1():55-60. PubMed ID: 19567215
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of systemic therapies for moderate to severe psoriasis.
Sizto S; Bansback N; Feldman SR; Willian MK; Anis AH
Br J Dermatol; 2009 Jun; 160(6):1264-72. PubMed ID: 19120346
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of biological therapy in remission induction of moderate to severe plaque psoriasis.
Schmitt-Rau K; Rosenbach T; Radtke MA; Augustin M
Dermatology; 2010; 221(3):236-42. PubMed ID: 20924159
[TBL] [Abstract][Full Text] [Related]
8. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
[TBL] [Abstract][Full Text] [Related]
9. Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis.
Kirson NY; Rao S; Birnbaum HG; Kantor E; Wei RS; Cifaldi M
J Med Econ; 2013; 16(4):479-89. PubMed ID: 23339434
[TBL] [Abstract][Full Text] [Related]
10. Costs of therapy with biologics in the treatment of moderate to severe plaque psoriasis in the context of the Italian health-care system.
Terranova L; Mattozzi C; Richetta AG; Mantuano M; Cardosi L; Teruzzi C
G Ital Dermatol Venereol; 2014 Feb; 149(1):131-43. PubMed ID: 24566574
[TBL] [Abstract][Full Text] [Related]
11. Cost utility analysis based on a head-to-head Phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective.
Pan F; Brazier NC; Shear NH; Jivraj F; Schenkel B; Brown R
Value Health; 2011; 14(5):652-6. PubMed ID: 21839402
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of etanercept in the management of chronic plaque psoriasis.
Lloyd A; Reeves P; Conway P; Reynolds A; Baxter G
Br J Dermatol; 2009 Feb; 160(2):380-6. PubMed ID: 18808413
[TBL] [Abstract][Full Text] [Related]
13. Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis.
Martin S; Feldman SR; Augustin M; Szapary P; Schenkel B
J Dermatolog Treat; 2011 Jun; 22(3):138-43. PubMed ID: 21254886
[TBL] [Abstract][Full Text] [Related]
14. Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis.
Bojke L; Epstein D; Craig D; Rodgers M; Woolacott N; Yang H; Sculpher M
Rheumatology (Oxford); 2011 Sep; 50 Suppl 4():iv39-iv47. PubMed ID: 21859705
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of psoriasis therapy with etanercept in Germany.
Heinen-Kammerer T; Daniel D; Stratmann L; Rychlik R; Boehncke WH
J Dtsch Dermatol Ges; 2007 Sep; 5(9):762-8. PubMed ID: 17760896
[TBL] [Abstract][Full Text] [Related]
16. Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis.
Wailoo AJ; Bansback N; Brennan A; Michaud K; Nixon RM; Wolfe F
Arthritis Rheum; 2008 Apr; 58(4):939-46. PubMed ID: 18383356
[TBL] [Abstract][Full Text] [Related]
17. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis.
Langley RG; Strober BE; Gu Y; Rozzo SJ; Okun MM
Br J Dermatol; 2010 Jun; 162(6):1349-58. PubMed ID: 20394634
[TBL] [Abstract][Full Text] [Related]
18. [Efficiency of biologic agents in the treatment of moderate to severe psoriasis].
Blasco AJ; Lázaro P; Ferrándiz C; García-Díez A; Liso J
Actas Dermosifiliogr; 2009 Nov; 100(9):792-803. PubMed ID: 19889301
[TBL] [Abstract][Full Text] [Related]
19. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.
Vender R
J Drugs Dermatol; 2011 Apr; 10(4):396-402. PubMed ID: 21455550
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States.
Anis AH; Bansback N; Sizto S; Gupta SR; Willian MK; Feldman SR
J Dermatolog Treat; 2011 Apr; 22(2):65-74. PubMed ID: 20443663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
